PHGE
BiomX Inc.1.5500
-0.1800-10.4%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
2.37MP/E (TTM)
-Basic EPS (TTM)
-37.05Dividend Yield
0%Recent Filings
8-K
Warrant amended, overhang eased
BiomX amended its December 2025 warrant on March 13, 2026, slashing the exercise price to $1.00 per share for 3.3M common shares and shortening expiration to December 31, 2026. This resolves investor overhang from long-dated warrants, simplifying capital structure amid leadership changes and cost cuts. Warrants now less valuable per option models. CEO eyes defense sector pivots.
8-K
Stockholders approve share issuance
BiomX stockholders approved Proposal No. 1 at the March 11, 2026 special meeting, authorizing issuance of common shares underlying Series Y preferred stock and warrants from a December 26, 2025 securities purchase agreement—528,511 for, 23,714 against. This clears NYSE American compliance hurdles for the financing. No adjournment needed. Stockholders fully participated.
8-K
CEO, Chairman resign; replacements named
BiomX Inc. saw swift leadership shakeup on March 4, 2026: CEO Jonathan Solomon and Chairman Dr. Russell Greig resigned without disagreements, paving way for Michael Oster's immediate CEO appointment and Amir Shalom's board addition. New execs bring operational heft from energy and medical imaging. Committees realigned March 5. Leadership reset complete.
8-K
Exec resignations, new CFO
BiomX lost CFO Marina Wolfson and Chief Development Officer Dr. Merav Bassan on February 24, 2026, followed by three directors resigning the next day—none citing disagreements. Board swiftly named finance veteran David Rokach as new CFO on February 27. Special meeting adjourned for quorum failure; reconvenes March 11. Leadership shakeup tests continuity.
8-K
Board shakeup adds finance pros
BiomX Inc. saw director Alan Moses resign on February 19, 2026, for personal reasons, with no disagreements noted. The board quickly filled vacancies by appointing investment experts Guy Arieli and Shaked Ran on February 25, both NYSE American independent. New directors get standard prorated pay. Board refresh bolsters financial oversight.
ARMP
Armata Pharmaceuticals, Inc.
5.72-0.44
BLRX
BioLineRx Ltd.
3.01-0.17
EVFM
Evofem Biosciences, Inc.
0.01-0.00
IMMX
Immix Biopharma, Inc.
5.94-0.27
MBX
MBX Biosciences, Inc.
27.75-0.63
PASG
Passage Bio, Inc.
9.45-0.60
PBM
Psyence Biomedical Ltd.
1.53+0.05
PHAT
Phathom Pharmaceuticals, Inc.
15.24+0.55
PHIO
Phio Pharmaceuticals Corp.
1.08-0.01
XLO
Xilio Therapeutics, Inc.
0.65+0.00